Amarin reports positive data for Vascepa
Amarin Corporation plc (AMRN) provided new supporting data about the potential of its flagship product Vascepa in treating patients with persistent cardiovascular risk. Vascepa is the first and only agent analyzed on top of statin therapy reported to have shown coronary plaque regression in hypertriglyceridemic patients.
EVAPORATE trial is a randomized, double-blind, placebo-controlled study. It enrolled 80 patients with coronary atherosclerosis as documented by MDCT, on statin therapy, and have persistently elevated triglyceride ((TG)) levels. Vascepa showed significant, 17 percent regression of low attenuation plaque (LAP) volume